Holen Sie sich die Stockscreener-App
54.14
1.18%
0.63
Handel nachbörslich:
54.14
Schlusskurs vom Vortag:
$53.51
Offen:
$53.86
24-Stunden-Volumen:
128.45K
Relative Volume:
0.92
Marktkapitalisierung:
$598.77M
Einnahmen:
-
Nettoeinkommen (Verlust:
-
KGV:
-
EPS:
-
Netto-Cashflow:
-
1W Leistung:
+5.54%
1M Leistung:
+45.54%
6M Leistung:
+161.55%
1J Leistung:
+0.00%
1-Tages-Spanne:
$51.54
$54.15
1-Wochen-Bereich:
$49.81
$56.77
52-Wochen-Spanne:
$11.17
$57.19
Palvella Therapeutics Inc Stock (PVLA) Company Profile
Firmenname
Palvella Therapeutics Inc
Sektor
Branche
Telefon
(484) 253-1461
Adresse
125 STRAFFORD AVE, WAYNE
Vergleichen Sie PVLA mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
PVLA
Palvella Therapeutics Inc
|
54.14 | 582.95M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
396.93 | 102.81B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
453.54 | 58.59B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
567.22 | 61.25B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
733.66 | 43.23B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
318.73 | 36.53B | 3.81B | -644.79M | -669.77M | -6.24 |
Palvella Therapeutics Inc Stock (PVLA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-08-06 | Eingeleitet | Raymond James | Outperform |
| 2025-07-21 | Eingeleitet | Truist | Buy |
| 2025-04-09 | Eingeleitet | Chardan Capital Markets | Buy |
| 2025-03-26 | Eingeleitet | Stifel | Buy |
| 2025-03-07 | Eingeleitet | Scotiabank | Sector Outperform |
| 2025-02-20 | Eingeleitet | Canaccord Genuity | Buy |
| 2025-02-05 | Eingeleitet | TD Cowen | Buy |
| 2024-12-26 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-12-18 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2020-03-13 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2019-07-30 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2019-05-14 | Eingeleitet | Robert W. Baird | Outperform |
| 2018-03-19 | Eingeleitet | Evercore ISI | Outperform |
| 2018-03-19 | Eingeleitet | Jefferies | Buy |
| 2018-01-16 | Bestätigt | H.C. Wainwright | Buy |
| 2017-05-30 | Eingeleitet | Rodman & Renshaw | Buy |
| 2016-08-05 | Fortgesetzt | ROTH Capital | Buy |
| 2015-08-12 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2015-07-27 | Eingeleitet | Oppenheimer | Outperform |
| 2015-07-22 | Eingeleitet | ROTH Capital | Buy |
Alle ansehen
Palvella Therapeutics Inc Aktie (PVLA) Neueste Nachrichten
What is Palvella Therapeutics Inc. s debt to equity ratioBond Market & Low Volatility Stock Recommendations - khodrobank.com
Using data models to predict Palvella Therapeutics Inc. stock movementBond Market & Free Community Consensus Stock Picks - Newser
Does Palvella Therapeutics Inc. fit your quant trading modelTrade Signal Summary & Long-Term Safe Investment Plans - Newser
News impact scoring models applied to Palvella Therapeutics Inc.2025 Macro Impact & Verified Momentum Watchlists - Newser
Palvella Therapeutics Appoints David W. Osborne, Ph.D. as Chief Innovation Officer - citybiz
Palvella Therapeutics shares fall 2.52% intraday after appointing new chief innovation officer. - AInvest
Palvella Therapeutics Inc.’s volatility index tracking explainedMarket Volume Summary & Reliable Momentum Entry Alerts - Newser
Can you recover from losses in Palvella Therapeutics Inc.2025 Top Gainers & Daily Volume Surge Signals - Newser
Palvella Therapeutics appoints David Osborne as chief innovation officer - Investing.com
Palvella Therapeutics Accelerates U.S. Launch Planning - TipRanks
Palvella Therapeutics Strengthens Leadership with Appointment of Accomplished Scientist and Biopharmaceutical Executive David W. Osborne, Ph.D. as Chief Innovation Officer - The Manila Times
Palvella Therapeutics Inc. stock outlook for YEARWeekly Gains Summary & Real-Time Volume Spike Alerts - Newser
Palvella Therapeutics Strengthens Leadership with - GlobeNewswire
David Osborne Appointed Chief Innovation Officer at Palvella Therapeutics - AInvest
Former Arcutis CTO with 52 US Patents Joins Palvella Therapeutics to Expand Rare Skin Disease Platform - Stock Titan
Using flow based indicators on Palvella Therapeutics Inc.Quarterly Earnings Summary & Entry Point Confirmation Alerts - Newser
Using RSI to spot recovery in Palvella Therapeutics Inc.July 2025 Selloffs & Weekly High Return Stock Forecasts - Newser
Applying Elliott Wave Theory to Palvella Therapeutics Inc.July 2025 Snapshot & Safe Capital Allocation Plans - Newser
Is this a good reentry point in Palvella Therapeutics Inc.Market Trend Review & Free Real-Time Volume Trigger Notifications - Newser
What high frequency data says about Palvella Therapeutics Inc.July 2025 Macro Moves & AI Forecasted Stock Moves - Newser
Statistical indicators supporting Palvella Therapeutics Inc.’s strengthMarket Growth Report & Expert Approved Momentum Trade Ideas - Newser
Key metrics from Palvella Therapeutics Inc.’s quarterly dataPortfolio Return Summary & Low Risk Growth Stock Ideas - Newser
Is Palvella Therapeutics Inc. stock ready for a breakoutChart Signals & Capital Protection Trade Alerts - Newser
Is Palvella Therapeutics Inc. showing signs of accumulation2025 Earnings Impact & Weekly Top Gainers Trade List - Newser
Is Palvella Therapeutics Inc. stock poised for growth2025 Market WrapUp & Fast Momentum Stock Entry Tips - Newser
How sensitive is Palvella Therapeutics Inc. to inflationMarket Sentiment Report & Weekly Chart Analysis and Guides - خودرو بانک
Quantitative breakdown of Palvella Therapeutics Inc. recent moveRate Cut & Free Fast Gain Swing Trade Alerts - Newser
Multi asset correlation models including Palvella Therapeutics Inc.Weekly Stock Report & AI Enhanced Trade Execution Alerts - Newser
Using portfolio simulators with Palvella Therapeutics Inc. includedShare Buyback & Low Drawdown Momentum Ideas - Newser
Palvella Therapeutics Inc. stock retracement – recovery analysisQuarterly Portfolio Review & Entry Point Confirmation Signals - Newser
What is the next catalyst for Palvella Therapeutics Inc.2025 Breakouts & Breakdowns & AI Enhanced Trading Alerts - khodrobank.com
What are analysts’ price targets for Palvella Therapeutics Inc.Portfolio Update Summary & Weekly Breakout Stock Alerts - khodrobank.com
Candlestick Signal Suggests Reversal in Palvella Therapeutics Inc. getLinesFromResByArray error: size == 0 - thegnnews.com
News impact scoring models applied to Palvella Therapeutics IncBuy Signal & Accurate Entry and Exit Point Alerts - Newser
Finanzdaten der Palvella Therapeutics Inc-Aktie (PVLA)
Es liegen keine Finanzdaten für Palvella Therapeutics Inc (PVLA) vor. Überprüfen Sie andere Aktien für weitere Informationen.
Umsatz
Nettogewinn
Free Cashflow
ENV
Palvella Therapeutics Inc-Aktie (PVLA) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| JENKINS GEORGE M | Director |
Apr 09 '25 |
Buy |
20.13 |
2,500 |
50,325 |
183,171 |
| JENKINS GEORGE M | Director |
Dec 18 '24 |
Buy |
12.93 |
4,000 |
51,720 |
180,671 |
1.75%
1.11%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):